Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment guidelines news

Show

From To
Medicare decides against tighter management of HIV drugs

The Department of Health and Human Services will continue barring Medicare Part D plans from applying the drug utilization management tools prior authorization and step therapy for beneficiaries taking HIV antiretroviral drugs. A rule proposed in November 2018 would have permitted such practices. Gilead voiced opposition to the original proposal, saying physicians need to have the flexibility to prescribe the right medicines for patients.

Published
21 May 2019
From
BioPharma Dive
U.S. Revises Pediatric HIV Treatment Guidelines

Changes include new information about risks associated with Tivicay during pregnancy and a removal of older drugs owing to toxicities.

Published
23 April 2019
From
Poz
Avoiding Dolutegravir in Young Women With HIV: Time for a Rethink?

Total deaths for women with HIV and their children are projected to be lower with dolutegravir-based (Tivicay) antiretroviral therapy (ART) versus efavirenz-based (Sustiva) ART, a model-based analysis found.

Published
05 April 2019
From
MedPage Today
For Our Stable HIV Patients, Why Are We Still Sending All These Lab Tests So Often?

Do the guidelines for laboratory monitoring still make sense when our HIV treatments have become so safe and effective?

Published
29 January 2019
From
NEJM Journal Watch
Dolutegravir- why new does not automatically mean better

As has been previously reported by Spotlight, a new and exciting anti-retroviral, dolutegravir, is soon to become widely available in South Africa. Whilst its very real advantages have been extensively reported, the potential disadvantages have received relatively little attention.

Published
25 January 2019
From
Spotlight
HIV care is threatened by proposed changes to Medicare Part D

Optimal HIV care includes early and uninterrupted access to effective antiretroviral medications. Proposed changes to Medicare Part D threatens that.

Published
25 January 2019
From
STAT
What's New in the U.S. HIV Clinical Guidelines

We walk you through the most recent updates to official guidelines issued by the U.S. Department of Health and Human Services on the treatment and care of HIV.

Published
21 December 2018
From
TheBody.com
How HIV Physicians Can Better Treat an Aging Population

A research team has sought to address the critical lack of treatment guidelines for addressing HIV’s complex effects on aging.

Published
12 December 2018
From
Poz
Brazil highlights treatment for all people with HIV

Ahead of World AIDS Day 2018, the Government of Brazil has announced the largest drop in AIDS-related deaths in the country, as a result of Brazil’s policy for greater access to HIV prevention, testing, treatment and care.

Published
01 December 2018
From
World Health Organization
Focus on HIV-2 Infection: A Clinician Roundtable

Infectious Disease Advisor interviewed the following experts to discuss the challenges and clinical implications pertaining to HIV-2.

Published
04 September 2018
From
Infectious Disease Advisor
← First12345...25Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.